RE: Iclaprim18 Jul 2020 13:28
Even well before the Lamellar connection there were those in the UK Pharma community who said that Motif would have been better going for respiratory indications rather than skin. Unfortunately, and for whatever reasons, they chose the other route. But perhaps it is not too late.